Nanoelectronics specialist Imec will demonstrate a miniaturised, ingestible sensor device today that can monitor ...

Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the ...

After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug ...

Guidance on the new policy from the Department for Science, Innovation and Technology (DSIT) notes that qualifying for ...

The data used to train the AI – including vaccination records, GP visits, hospital admissions, and A&E attendances – is being ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets. In a new ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical ...